Pharmacological Treatment for Alcoholism

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

283 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-06-30

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to learn whether ondansetron is safe and effective in the treatment of alcohol dependence. We also want to learn whether the study drug ondansetron combined with Cognitive Behavioral Therapy will assist researchers to determine whether having a certain gene is responsible for determining how a person benefits or does not benefit from the use of ondansetron for alcohol dependence.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ondansetron With Olanzapine for the Treatment of Alcohol Dependence: A Preliminary Clinical Trial

NCT00678457

Alcohol Dependence

COMPLETED PHASE2

Pharmacogenetic Treatments for Alcoholism

NCT01591291

Alcoholism

WITHDRAWN PHASE2/PHASE3

Alcohol Dependency Study: Combining Medication Treatment for Alcoholism

NCT00006205

Alcoholism

UNKNOWN PHASE2

Combined Pharmacotherapies for Alcoholism

NCT00768508

Alcoholism

COMPLETED PHASE3

Ondansetron Treatment for Alcoholism

NCT00000443

Alcoholism

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a 13 week outpatient clinical trial. Participants will either receive ondansetron or placebo and behavioral therapy. There is a 1, 2, and 3 month post-study follow up visit.Screening for this study is initially done over the telephone and takes 15-20 minutes. If participants are eligible after the initial screen, they will be invited to come in for a more thorough in house screen which takes about 5 to 6 hours. The screening will include a physical exam, review of medical, alcohol and drug histories and blood collection. If participants are found to be eligible after the in house screen, they will be enrolled in the 13 week outpatient clinical trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcohol Dependence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ondansetron

Arm 1 = Ondansetron 4 mcg/kg b.i.d.+ Cognitive behavioral therapy

Group Type EXPERIMENTAL

Ondansetron + Cognitive Behavioral Therapy

Intervention Type DRUG

13 week outpatient trial

Placebo

Arm 2 = Placebo + Cognitive behavioral therapy

Group Type PLACEBO_COMPARATOR

Placebo + Cognitive Behavioral Therapy

Intervention Type DRUG

13 week outpatient trial

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ondansetron + Cognitive Behavioral Therapy

13 week outpatient trial

Intervention Type DRUG

Placebo + Cognitive Behavioral Therapy

13 week outpatient trial

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Zofran Sugar Pill

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females who have given written informed consent.
* Ages 18 years and above and, must weigh at least 40 Kg and no more than 140 Kg
* Good physical health as determined by a complete physical examination, an EKG within normal limits, and laboratory screening tests within acceptable parameters.
* Audit score equal or more than 8
* Current DSM-IV diagnosis of alcohol dependence
* Currently drinking equal or more than 14 alcohol units/week for women and equal or more than 21 alcohol units/week for men in the last 30 days.
* Provide evidence of stable residence in the last month prior to enrollment in the study, and have no plans to move in the next three months.
* The pregnancy test for females at intake must be negative. Additionally, women of childbearing potential must be using an acceptable form of contraception. These include: oral contraceptives, hormonal (levonorgestrel) or surgical implants, or barrier plus spermicide.
* Literate in English and able to read, understand, and complete the ratings scales and questionnaires accurately, follow instructions, and make use of the behavioral treatments.
* Answer an advertisement in the newspaper/radio/television, and express a wish to stop drinking.
* Willingness to participate in behavioral treatments for alcoholism.

Exclusion Criteria

* Subjects who are legally mandated to participate in an alcohol treatment program.
* Any current axis I DSM IV psychiatric disorder other than alcohol or nicotine dependence
* Elevation of liver enzymes - (SGOT), serum glutamic pyruvic transaminase (SGPT), blood urea nitrogen (BUN), or lactate dehydrogenase (LDH) greater than four times the normal range, or clinically significant elevated direct bilirubin as deemed by the principal investigator.
* Severe alcohol withdrawal symptoms which in the physicians opinion requires inpatient treatment.
* Serious medical co-morbidity requiring medical intervention or close supervision, or any condition, which can interfere with the receipt of ondansetron.
* Severe or life-threatening adverse reactions to ondansetron or similar medication either in the past or during this clinical trial.
* Female patients who are pregnant, lactating, or not adhering to an acceptable form of contraception at any time during the study.
* Received inpatient or outpatient treatment for alcohol dependence within the last 30 days (support groups such as AA are not exclusionary).
* Compelled to participate in an alcohol treatment program to maintain their liberty.
* Members of the same household.
* Treated with any medications having a potential effect on alcohol consumption and related behaviors, or mood. These include: opiate antagonist (e.g. naltrexone), glutamate antagonists (e.g., acamprosate), serotonin re-uptake inhibitors (e.g. fluoxetine), serotonin antagonists (e.g. ritanserin or buspirone), other antidepressants (e.g. tricyclic antidepressants or monoamine oxidase inhibitors), dopamine antagonists (e.g. haloperidol), calcium channel antagonists (e.g. isradipine), or compounds with actions similar to disulfiram (antabuse) or nicotine.
* Before double-blind randomization, urine must be free of opiates, cocaine, amphetamines, barbiturates, benzodiazepines, prescription and non-prescription drugs.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No